Why this company's Durham outpost may benefit from $100M investment

Massachusetts-based gene therapy company bluebird bio (Nasdaq: BLUE) – which is growing in Durham – has inked a $100 million deal for the development of treatments for cancer. Bluebird said Monday that it will collaborate with New York-based Regeneron Pharmaceuticals (Nasdaq: REGN) on those potential treatments and that, as part of the deal, Regeneron will make a $100 million investment in the company’s common stock “at a price of $238.10 per share, which represents a premium of 59 percent…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news